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by Anna B. Laakmann ........................................................................... 917 
The Drug Price Competition and Patent Term Restoration Act of 1984 
(generally known as the Hatch-Waxman Act, or “Hatch-Waxman”) was 
designed to expedite regulatory approval of generic drugs while simultaneously 
preserving incentives for innovators to invest in the research and development 
of new drugs. While Hatch-Waxman has undoubtedly achieved its aim of 
creating a robust generic pharmaceuticals market, it has also produced several 
unanticipated consequences. Its changes to the federal regulatory scheme have 
yielded convoluted products liability rules, upsetting the conventional notion 
that the seller of a defective product is liable for harm caused by its intended 
use. In addition, its modifications to patent law have had the perverse effects of 
propagating patents of questionable value and encouraging potentially anti-
competitive agreements between generic and brand name manufacturers.  
       Hatch-Waxman’s emergent repercussions are particularly salient in light of 
the recent passage of the Biologics Price Competition and Innovation Act 
(BPCIA). The BPCIA, enacted as part of the Patient Protection and Affordable 
Care Act of 2010, crafted a compromise between pioneer and follow-on 
biologics manufacturers patterned after Hatch-Waxman’s regulatory scheme 
for pharmaceuticals. This Article reviews Hatch-Waxman unintended effects, 
and suggests that they should serve as precautionary guideposts for 
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implementation of the BPCIA. The FDA and lawmakers should heed these 
potential pitfalls and proactively confront unavoidable tradeoffs between 
safety, cost, and access to therapeutic biologics. 
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The American health care system is plagued by high costs and poor public 
health outcomes, due in part to the overuse of costly diagnostic tests and 
treatments. In 2009, the Institute of Medicine estimated that unnecessary care 
wastes $750 billion, equivalent to about 30 percent of health care spending. 
Moreover, overtreatment can directly harm patients as a result of surgical 
complications, drug toxicity, and hospital-acquired infections. 
       Yet while the problem of medical waste has long been recognized, 
solving the problem has proven elusive. In part, this difficulty is due to 
perverse economic incentives for physicians and hospitals, which still 
primarily receive reimbursement on a fee-for-service basis. Providers are 
financially motivated under this system to generate a higher volume of 
invasive procedures independent of their likely benefits. Patients generally 
lack the information needed to decline unnecessary services, even when they 
wish to actively share in medical decision-making, and a strong cultural bias 
pushes both patients and physicians to “do more,” even when evidence 
suggests that doing more may result in harm. In the 1990s, managed health 
care organizations attempted to rein in health care waste by stringently 
reviewing and prospectively denying payment for unnecessary tests and 
treatments, but that experiment was a political failure. Similarly, attempts to 
reduce overuse by shifting financial risk directly onto providers through 
capitated payment mechanisms have had limited success. The ability of these 
mechanisms to limit waste is compromised by the real or perceived incentive 
to also reduce spending on appropriate care. 
       We propose a new conception of medical necessity that will reduce 
inappropriate care by allowing informed consumers to actively participate in 
decisions about their medical care. Where evidence-based guidelines are 
available, medical necessity should be determined on the basis of an 
objective, multi-level Matrix of Appropriateness rather than the subjective 
binary decision of an insurance company’s medical reviewer. Such Matrices 
have already been created by systematically combining published evidence 
with expert judgment to create clinically detailed, evidence-based, multi-
level medical necessity ratings for elective procedures based on individual 
patient characteristics. In our proposed system, if a patient desires a service 
proposed by a physician under clinical circumstances that receive low 
medical necessity ratings, the third-party payer would offer to cover the 
service but at a sliding co-payment scale imposing greater patient cost 
sharing based on the service’s appropriateness. This system would preserve 
patient choice while discouraging the overuse of costly treatments that 
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provide little marginal value, reducing medical waste and improving the 
overall value of medical care. 
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